News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UbiQ Secures 2.7 mioEUR EUROSTARS Grant To Tackle SUMOylation



9/13/2017 10:35:55 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Amsterdam, The Netherlands, September 12th, 2017: UbiQ, a biotech company focused on the development and commercialization of research tools and small molecule drugs targeting the ubiquitin system, has been awarded a 2.7 mioEUR EUROSTARS grant for the pre-clinical development of a targeted therapy for Diffuse Large B-cell Lymphoma (DLBCL).

The EUROSTARS grant (with the acronym; SUBLYME*) will enable UbiQ to advance its mechanism-based covalent SUMOylation inhibitor through pre-clinical development. The work will be performed by UbiQ and French, German and Swedish life-science companies as European Consortium Partners in SUBLYME. The Technische Universität München (TUM) is participating as the leading academic partner; Prof Ulrich Keller, deputy head of the Department of Haematology/Oncology, is a key opinion leader in the molecular treatment of lymphoma malignancies. TUM will be involved in validation and mechanistic studies of the novel DLBCL treatment strategy in both primary human material and unique cell lines and mouse models developed in the SUBLYME project. “Our work has validated the enzymes responsible for protein SUMOylation as promising targets for the treatment of cancers such as B cell lymphomas. We are excited that, with this grant, we can make a start to bring UbiQ’s SUMOylation inhibitors to the clinic.”  

“SUBLYME scored very high in the EUROSTARS ranking system that takes into account the level of innovation, market need and potential. The project scored as number 31 of 376 EUROSTARS applications at the European level”, says Boris Rodenko, VP Translational Drug Discovery of UbiQ.


About UbiQ

UbiQ is a spin-out of the Netherlands Cancer Institute and based at the Amsterdam Science Park in the Netherlands. UbiQ has generated some of the first commercially available custom ubiquitinated peptides and now distributes a whole range of ubiquitin-related reagents worldwide. In addition to enabling drug discovery in the rapidly expanding ubiquitin research field, UbiQ is also actively developing small molecule inhibitors that target the ubiquitin system. UbiQ’s Triple E technology exploits a reactive group that specifically traps the E1, E2 and E3 ubiquitinating enzymes. By adding this ‘hook’ onto ubiquitin itself or onto a peptide or small molecule, it has now, for the first time, become possible to specifically monitor and block the activity of dozens of enzymes involved in protein ubiquitination. This technology was published in Nature Chemical Biology in May 2016. More information can be found on the company website www.ubiqbio.com.
Read at BioSpace.com


comments powered by Disqus
UbiQ
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES